Compound of formula wherein: A is selected from H or CF 3; B is selected from H, COOH or COOR 1; ring Hy is selected from: C is selected from unsubstituted or substituted C 1-8 alkyl group, unsubstituted or substituted C 2-8 alkenyl group, unsubstituted or substituted C 2-8 alkynyl group, unsubstituted or substituted C 3-6 cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic group, (CH 2) m -C 1-8 alkyl, (CH 2) m -C 2-8 alkenyl, (CH 2) m -C 2-8 alkynyl group, (CH 2) m -cycloalkyl, (CH 2) m -aryl and (CH 2) m -heterocyclic group, wherein m is an integer 1 to 4; R 1 is selected from unsubstituted or substituted C 1-8 alkyl group, unsubstituted or substituted C 2-8 alkenyl group, unsubstituted or substituted C 2-8 alkynyl group, unsubstituted or substituted C 3-6 cycloalkyl,, unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic group, (CH 2) n -C 1-8 alkyl, (CH 2) n -C 2-8 alkenyl, (CH 2) n -C 2-8 alkynyl group, n-cycloalkyl, n-aryl and (CH 2) n -heteroaryl, wherein n is an integer 1 to 4; wherein the one or more substituents of C and R 1 are independently selected from halogen, -CH 3, -CH 2 F, -CHF 2, -CF 3, -OR 2, -CN, -COOR 2, -CONR 2 R 3,-NR 2 R 3, -NHCOR 2, -NHSO 2 R 2, -S R 2, -S 2 R 2, and -SO 2 NHR 2; wherein R 2 and R 3 are the same or different and independently selected from H, unsubstituted or substituted C 1 -C 8 alkyl group and unsubstituted or substituted C 3 -C 6 cycloalkyl group, wherein the one or more substituents of R 2 and R 3 are selected from halogen atoms. pharmaceutically acceptable hydrates and/or solvates and/or salts and/or esters thereof. A is selected from H or CF 3; B is selected from H, COOH or COOR 1; ring Hy is selected from: C is selected from unsubstituted or substituted C 1-8 alkyl group, unsubstituted or substituted C 2-8 alkenyl group, unsubstituted or substituted C 2-8 alkynyl group, unsubstituted or substituted C 3-6 cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic group, (CH 2) m -C 1-8 alkyl, (CH 2) m -C 2-8 alkenyl, (CH 2) m -C 2-8 alkynyl group, (CH 2) m -cycloalkyl, (CH 2) m -aryl and (CH 2) m -heterocyclic group, wherein m is an integer 1 to 4; R 1 is selected from unsubstituted or substituted C 1-8 alkyl group, unsubstituted or substituted C 2-8 alkenyl group, unsubstituted or substituted C 2-8 alkynyl group, unsubstituted or substituted C 3-6 cycloalkyl,, unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic group, (CH 2) n -C 1-8 alkyl, (CH 2) n -C 2-8 alkenyl, (CH 2) n -C 2-8 alkynyl group, n-cycloalkyl, n-aryl and (CH 2) n -heteroaryl, wherein n is an integer 1 to 4; wherein the one or more substituents of C and R 1 are independently selected from halogen, -CH 3, -CH 2 F, -CHF 2, -CF 3, -OR 2, -CN, -COOR 2, -CONR 2 R 3,-NR 2 R 3, -NHCOR 2, -NHSO 2 R 2, -S R 2, -S 2 R 2, and -SO 2 NHR 2; wherein R 2 and R 3 are the same or different and independently selected from H, unsubstituted or substituted C 1 -C 8 alkyl group and unsubstituted or substituted C 3 -C 6 cycloalkyl group, wherein the one or more substituents of R 2 and R 3 are selected from halogen atoms. pharmaceutically acceptable hydrates and/or solvates and/or salts and/or esters thereof. C is selected from unsubstituted or substituted C 1-8 alkyl group, unsubstituted or substituted C 2-8 alkenyl group, unsubstituted or substituted C 2-8 alkynyl group, unsubstituted or substituted C 3-6 cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic group, (CH 2) m -C 1-8 alkyl, (CH 2) m -C 2-8 alkenyl, (CH 2) m -C 2-8 alkynyl group, (CH 2) m -cycloalkyl, (CH 2) m -aryl and (CH 2) m -heterocyclic group, wherein m is an integer 1 to 4; R 1 is selected from unsubstituted or substituted C 1-8 alkyl group, unsubstituted or substituted C 2-8 alkenyl group, unsubstituted or substituted C 2-8 alkynyl group, unsubstituted or substituted C 3-6 cycloalkyl,, unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic group, (CH 2) n -C 1-8 alkyl, (CH 2) n -C 2-8 alkenyl, (CH 2) n -C 2-8 alkynyl group, n-cycloalkyl, n-aryl and (CH 2) n -heteroaryl, wherein n is an integer 1 to 4; wherein the one or more substituents of C and R 1 are independently selected from halogen, -CH 3, -CH 2 F, -CHF 2, -CF 3, -OR 2, -CN, -COOR 2, -CONR 2 R 3,-NR 2 R 3, -NHCOR 2, -NHSO 2 R 2, -S R 2, -S 2 R 2, and -SO 2 NHR 2; wherein R 2 and R 3 are the same or different and independently selected from H, unsubstituted or substituted C 1 -C 8 alkyl group and unsubstituted or substituted C 3 -C 6 cycloalkyl group, wherein the one or more substituents of R 2 and R 3 are selected from halogen atoms. pharmaceutically acceptable hydrates and/or solvates and/or salts and/or esters thereof.